GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (XBUL:JNJ) » Definitions » Net Change in Cash

Johnson & Johnson (XBUL:JNJ) Net Change in Cash : лв3,878 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Johnson & Johnson Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Johnson & Johnson's Net Change in Cash for the three months ended in Dec. 2024 was лв7,121 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was лв3,878 Mil.

Johnson & Johnson Net Change in Cash Historical Data

The historical data trend for Johnson & Johnson's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Net Change in Cash Chart

Johnson & Johnson Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,731.72 866.66 -621.51 13,348.70 3,877.55

Johnson & Johnson Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,679.01 6,239.29 -1,027.22 -8,456.02 7,121.50

Johnson & Johnson Net Change in Cash Calculation

Johnson & Johnson's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=41893.381+-32109.741+-5407.157+-498.936
=3,878

Johnson & Johnson's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=12055.612+-2278.878+-2313.407+-341.832
=7,121

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was лв3,878 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (XBUL:JNJ) » Definitions » Net Change in Cash
Comparable Companies
ABBV MRK AMGN PFE GILD BMY LLY BIIB OGN AMRN OCSE:NOVO B XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578
Traded in Other Exchanges
JNJ:USA JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK 0R34:UK JNJ0:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria JNJ:Argentina
Address
One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Website
https://www.jnj.com
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.